Questions? Remarks? Contact us: info@vaccelerate.eu.
Warum haben wir Husten und Schnupfen?
In unserer Studie MAK-5-50+ bestimmen wir mittels Schnelltest, welche Viren (Corona, Influenza A und B, Adeno, RSV) Erkältungssymptome bei Personen in ganz Deutschland hervorrufen. Die Tests funktionieren wie Corona-Tests, können aber fünf Viren anzeigen. Die Untersuchung geht über ein Jahr. Die Teilnehmenden bekommen die Tests per Post zugeschickt und melden die Ergebnisse online.
Sie können die Ergebnisse live hier verfolgen. Die Daten werden regelmäßig von uns aktualisiert. Weitere Informationen: https://vaccelerate.eu/mak-5-50/
Stichtaguntersuchung
Die Punktprävalenz (Stichtaguntersuchung) gibt an, wie viele Personen zu einem bestimmten Zeitpunkt von einer Krankheit oder einem Zustand betroffen sind. In diesem Fall gilt sie daher als eine Momentaufnahme der Häufigkeit von verschiedenen Erregern der Erkältungskrankheiten (SARS-CoV-2, Influenza A, Influenza B, ADV und RSV). n = 2.419 (76.5%) der MAK5 50+ Teilnehmenden haben am 15.12.2024 getestet und ihre Ergebnisse gemeldet. ADV ist mit n = 39 nachgewiesenen Infektionen der am häufigsten gemeldete Erreger, gefolgt von SARS-CoV-2 mit n = 37 und Influenza A mit n = 31.
Why do we have cough and colds?
In our MAK-5-50+ study, we use rapid tests to determine which viruses (COVID-19, Influenza A and B, Adenovirus, RSV) cause cold symptoms in people throughout Germany. The tests work like COVID tests, but can detect five viruses. The study covers the period of one year. Participants receive the tests by post and report the results online.
You can follow the results here. We will update the data regularly. Further information: https://vaccelerate.eu/mak-5-50/
Point Prevalence
The point prevalence indicates how many people are affected by a disease or condition at a certain point in time. In this case, it is therefore considered a snapshot of the frequency of various pathogens (SARS-CoV-2, influenza A, Influenza B, ADV and RSV). n = 2,419 (76.5%) of MAK5 50+ participants tested and reported their results on 15 December 2024. ADV is the most frequently reported pathogen with n = 39 detected infections, followed by SARS-CoV-2 with n = 37 and Influenza A with n = 31.
VACCELERATE
is the pan-European backbone for the acceleration of phase 2 & 3 COVID-19 vaccine trials. The overall objective is to connect all European stakeholders involved in vaccine development to provide a pan-European platform for clinical trial design and conduct.
Find out more about the actively enrolling clinical studies of VACCELERATE.
> 107.000 Volunteers
We have set up a database in which you can register if you are interested in participating in a clinical study.
491 Sites
The VACCELERATE Site Network is a platform for experienced clinical trial sites interested in conducting COVID-19 vaccine studies. You can register by answering a short questionnaire.
What is VACCELERATE about?
VACCELERATE and its partners strongly condemn Russia's attack on Ukraine in violation of international law. The Russian invasion of Ukraine is an indescribable assault on the pillars of our society: freedom, democracy, self-determination and integrity. Our full solidarity goes out to the Ukrainian people.
To express this solidarity, we have decided to deactivate the sites from Belarus and Russia that are represented in the VACCELERATE Site Network. We do not know individual political views and we apologize for the inconvenience. Unfortunately, in this situation we cannot make individual decisions but have to take a clear position. The protection of our values is paramount for us.
We hope that the political situation will change as soon as possible, so that we will be able to reverse this decision.
